Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Insys Therapeutics, Inc. | insy-ex991_7.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2017
Insys Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-35902 |
51-0327886 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
1333 S. Spectrum Blvd, Suite 100 Chandler, Arizona |
|
85286 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (602) 910-2617
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On May 16, 2017, Insys Therapeutics, Inc. (the “Company”) announced it is commencing a search for a new Chief Financial Officer (“CFO”). Darryl S. Baker, the Company’s current CFO, will remain with the Company in his current capacity until a successor is hired. Upon his separation from the Company, Mr. Baker will receive the benefits and severance to which he is entitled pursuant to his employment agreement, which was previously filed as Exhibit 10.8 to the Company’s Form S-1 Registration Statement (No. 333-173154) on April 25, 2013. A copy of the Company’s press release announcing the CFO transition is attached to this Current Report as Exhibit 99.1.
|
|
|
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated May 16, 2017 Announcing Chief Financial Officer Transition
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: May 16, 2017 |
|
|
|
Insys Therapeutics, Inc. |
||
|
|
|
|
|
|||
|
|
|
|
|
By: |
|
/s/ Darryl S. Baker |
|
|
|
|
|
|
|
Darryl S. Baker |
|
|
|
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated May 16, 2017 Announcing Chief Financial Officer Transition
|